They also looked at the gene expression data from an additional CRC patient cohort (Gene Expression Omnibus (GEO)) and observed higher expression of GPX4, FTH1, and FTL, and lower ACSL4 expression, which is associated with poorer 5-year overall survival only in male patients with KRAS-mutant tumors. This evidence concerns the gene KRAS and colorectal carcinoma.